Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07406789 | Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).(LUMInova) | not yet recruiting | Phase 2 | 100 | TNC Nutrición Terapéutica S.L.OTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05383196 | Onvansertib + Paclitaxel In TNBC | active not recruiting | Phase 1 / Phase 2 | 50 | Antonio Giordano, MDOTHER | 1 |
| Feb 11, 2026 |
| clinicaltrials |
| NCT07188246 | Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer(BRINK) | recruiting | Phase 2 | 40 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07376538 | Response-Based Local Therapy for Regionally Advanced Breast Cancer | recruiting | Phase 2 | 157 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06064812 | A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. | recruiting | Phase 1 / Phase 2 | 99 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07401537 | Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer | recruiting | Phase 2 | 416 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT02747004 | A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer(Next MONARCH 1) | active not recruiting | Phase 2 | 234 | Eli Lilly and CompanyINDUSTRY | 14 | Feb 6, 2026 | clinicaltrials |
| NCT06175390 | Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer(SKYLINE) | active not recruiting | Phase 2 | 81 | Institut CurieOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07394218 | ctDNA-guided Treatment Decision-making | recruiting | Phase 2 | 122 | Fudan UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07001241 | Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors | recruiting | Phase 2 | 134 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03808662 | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung | active not recruiting | Phase 2 | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04454437 | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments | active not recruiting | Phase 2 | 80 | Gilead SciencesINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 100 | Gilead SciencesINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT04680715 | Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer(RPOS+2) | recruiting | Phase 2 | 40 | Centre Antoine LacassagneOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07370506 | Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 36 | Tanta UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376629 | A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | enrolling by invitation | Phase 2 | 60 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01984138 | REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy(REVIVE) | active not recruiting | Phase 2 | 33 | Polly A. Niravath, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03804944 | Converting HR+ Breast Cancer Into an Individualized Vaccine(CBCV) | recruiting | Phase 2 | 100 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07367178 | Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer(SATROPIN) | not yet recruiting | Phase 2 | 30 | MedSIROTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07368543 | Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer(STORM) | not yet recruiting | Phase 2 | 216 | Fudan UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT05968144 | Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness(ADRIAN) | active not recruiting | Phase 1 / Phase 2 | 30 | University of Maryland, BaltimoreOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06715826 | Target-specific immunoPET Imaging of Breast Cancer | recruiting | Phase 1 / Phase 2 | 200 | RenJi HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07371208 | Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer(ST-A-TN) | recruiting | Phase 2 | 40 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07366840 | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure(BRIGHT) | not yet recruiting | Phase 2 / Phase 3 | 268 | Fudan UniversityOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | University of Alabama at BirminghamOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07359404 | Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | enrolling by invitation | Phase 2 | 60 | YING FANOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03879577 | Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | active not recruiting | Phase 2 | 53 | University of ChicagoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05693766 | Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort(INSIGHT) | recruiting | Phase 2 | 64 | Sonya ReidOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05933395 | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor(GERTRUDE) | recruiting | Phase 2 | 135 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07353437 | Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco) | not yet recruiting | Phase 2 | 334 | Fudan UniversityOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | active not recruiting | Phase 2 | 110 | Ana C Garrido-Castro, MDOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06682195 | Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) | recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05826964 | Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer | active not recruiting | Phase 2 | 24 | University of MiamiOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07336771 | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 60 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06967103 | QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer | recruiting | Phase 2 | 238 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327021 | MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC(NOGA) | recruiting | Phase 2 | 54 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04290793 | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | active not recruiting | Phase 2 / Phase 3 | 113 | Hebei Medical University Fourth HospitalOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07002177 | A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC | recruiting | Phase 1 / Phase 2 | 196 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04872985 | Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer | active not recruiting | Phase 2 | 140 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT01196936 | Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors(LDTam) | active not recruiting | Phase 2 | 84 | University of Alabama at BirminghamOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT03344965 | Olaparib In Metastatic Breast Cancer | active not recruiting | Phase 2 | 114 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT06690840 | Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients(AZALEA) | recruiting | Phase 2 | 45 | European Institute of OncologyOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03393845 | Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | active not recruiting | Phase 2 | 47 | Nancy Chan, MDOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04762979 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | active not recruiting | Phase 2 | 44 | Marina N SharifiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05728268 | Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index | recruiting | Phase 2 | 64 | Shantou Central HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2026source: clinicaltrials